Under the partnership, Pharmadule Morimatsu will provide modular facilities for the WuXi Biologics Singapore CRDMO Center project.

This strategic cooperation starts with the integrated modular plants for two important production facilities in the WuXi Biologics Singapore CRDMO Center, and will include design, manufacturing, factory acceptance testing (FAT), installation, commissioning, and validation. The Singapore CRDMO Center will adopt a new generation of modular fabrication with the majority of construction work taking place in Morimatsu’s workshop, where it will be built, assembled and FAT-tested. This allows the quality, schedule, cost, and risk associated with the project to be well managed and controlled; compared with conventional construction, this method also greatly shortens the project cycle.

Chris Chen, CEO of WuXi Biologics, commented, “Singapore is one of the most advanced pharmaceutical hubs in the world, as well as a critical part of our global biomanufacturing network. By leveraging Pharmadule Morimatsu’s expertise and experience, we are confident that our Singapore CRDMO Center will contribute to our track record in establishing global sites successfully as demonstrated by our greenfield site in Ireland, further enabling global partners with premier quality services and solutions.”

Mr. Weihua Tang, CEO of Morimatsu LifeSciences, commented, “WuXi Biologics is an important partner of our company, we are very delighted to cooperate with them once again. In this cooperation, Pharmadule Morimatsu will utilize a new generation of modular fabrication methods to assist WuXi Biologics in expanding production capacity, accelerating the empowerment of global pharmaceutical companies, reducing R&D costs, and benefiting patients worldwide.”